SCHEMBL1574765

SCHEMBL1574765

COc1cccc(NC(=O)N2CC(N3CCN(c4ccc(OC(F)(F)F)cc4)CC3)C2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.59
MAPT P10636 3/20 0.59
POLB P06746 2/20 0.59
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
MAPK1 P28482 3/20 0.52
HTT P42858 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
HSD17B10 Q99714 2/20 0.52
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 4/20 0.50
CCR3 P51677 2/20 0.50
GAA P10253 2/20 0.49
GRIN2B Q13224 5/20 0.48
TSHR P16473 1/20 0.48
GFER P55789 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
MCL1 Q07820 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574856 0.90 LMNA (0.48) LMNAMAPTPOLBMAPK1HTT
SCHEMBL1575220 0.89 MAPT (0.57) LMNAMAPTSMN1; SMN2HSD17B10GAA
SCHEMBL1574555 0.89 MAPT (0.54) LMNAMAPTPOLBNPC1MAPK1
SCHEMBL1574951 0.88 LMNA (0.65) LMNAMAPTPOLBNPC1MAPK1
SCHEMBL1574532 0.88 MAPT (0.50) LMNAMAPTPOLBMAPK1HTT
SCHEMBL1575145 0.88 POLB (0.51) LMNAMAPTPOLBCCR3NAMPT
SCHEMBL1574999 0.87 EPHX2 (0.53) LMNAMAPTHTTNAMPT
SCHEMBL1574715 0.87 POLB (0.50) LMNAMAPTPOLBCCR3NAMPT
SCHEMBL1574496 0.85 LMNA (0.48) LMNAMAPTMAPK1HSD17B10ALDH1A1
SCHEMBL1574414 0.85 MAPT (0.55) LMNAMAPTPOLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB LMNA 1076/4885MAPT 3908/4885POLB 4641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.